Risk of Guillain‐Barré Syndrome following Serogroup C Meningococcal Conjugate Vaccine in Quebec, Canada
Open Access
- 15 April 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (8) , e75-e77
- https://doi.org/10.1086/533469
Abstract
To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM197 conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.Keywords
This publication has 8 references indexed in Scilit:
- Guillain-Barré syndromeThe Lancet, 2005
- Effectiveness of a Mass Immunization Campaign Using Serogroup C Meningococcal Conjugate VaccinePublished by American Medical Association (AMA) ,2004
- Guillain-Barré syndromeThe Lancet, 1998
- Case Series Analysis of Adverse Reactions to Vaccines: A Comparative EvaluationAmerican Journal of Epidemiology, 1996
- The reporting sensitivities of two passive surveillance systems for vaccine adverse events.American Journal of Public Health, 1995
- Incidence of Guillain-Barre Syndrome in Ontario and Quebec, 1983–1989, Using Hospital Service DatabasesEpidemiology, 1994
- Confounding in Studies of Adverse Reactions to VaccinesAmerican Journal of Epidemiology, 1992
- AN EPIDEMIOLOGIC AND CLINICAL EVALUATION OF GUILLAIN-BARRÉ SYNDROME REPORTED IN ASSOCIATION WITH THE ADMINISTRATION OF SWINE INFLUENZA VACCINESAmerican Journal of Epidemiology, 1984